News & Events
April 25, 2016
New Database for Sharing MS Clinical Trial DataApril 25, 2016 Sharing Clinical Trial Data for Multiple Sclerosis Standardized and Pooled Data Available for Secondary Research New York and Tucson – April 25, 2016. A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators....
April 18, 2016
New TB Clinical Trial Data-Sharing Platform Available for ResearchersApril 18, 2016 New TB Clinical Trial Data-Sharing Platform Available for Researchers TUCSON, Ariz., April 18, 2016 — The Critical Path Institute (C-Path), the Special Programme for Research and Training in Tropical Diseases (TDR), TB Alliance, and St. George’s, University of London, are pleased to announce the launch of the TB-Platform for Aggregation...
March 30, 2016
CDISC, C-Path and TransCelerate Announce Availability of New and Updated Standards for COPD, Virology and DiabetesMarch 30, 2016 CDISC, C-Path and TransCelerate Announce Availability of New and Updated Standards for COPD, Virology and Diabetes Austin, TX – 30 March 2016 – The Clinical Data Interchange Standards Consortium (CDISC), the Critical Path Institute (C-Path) and TransCelerate BioPharma, Inc. (“TransCelerate”) today announce the open availability of new and updated CDISC...
February 23, 2016
Parkinson’s UK Announces Major Pharma Companies Sign Up to CPPMajor pharma companies sign up to groundbreaking Parkinson’s consortium Seven of the world’s largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and effective therapies for Parkinson’s. The Critical Path for Parkinson’s consortium will bring together leading academics; industry members AbbVie, AstraZeneca, Biogen, Eli Lilly and Company,...
November 13, 2015
C-Path’s Polycystic Kidney Disease Outcomes Consortium Secures EMA Qualification Opinion for Enrichment Biomarker in ADPKDNovember 13, 2015 C-Path’s Polycystic Kidney Disease Outcomes Consortium Secures EMA Qualification Opinion for Enrichment Biomarker in ADPKD TUCSON, Ariz., November 13, 2015 – The Critical Path Institute (C-Path) announced today that the European Medicines Agency (EMA) rendered a positive qualification opinion to C-Path’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) for total kidney volume (TKV) as a prognostic...